CytomX Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Income
CONDENSED STATEMENTS OF OPERA TIONS AND COMPREHENSIVE INCOME (LOSS)
(in thousands, except share and per share data)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Revenues | $10,258 | $50,917 |
| Operating expenses: | ||
| Research and development | 19,238 | 18,868 |
| General and administrative | 10,692 | 9,428 |
| Total operating expenses | 29,930 | 28,296 |
| Income (loss) from operations | (19,672) | 22,621 |
| Interest income | 1,490 | 955 |
| Other (expense) income, net | (7) | 11 |
| Income (loss) before income taxes | (18,189) | 23,587 |
| Provision for income taxes | 59 | 62 |
| Net income (loss) attributable to common stockholders | (18,248) | 23,525 |
| Other comprehensive income (loss): | ||
| Unrealized loss on investments, net of tax | (9) | (28) |
| Total comprehensive income (loss) | $(18,257) | $23,497 |
| Net income (loss) per share: | ||
| Basic | $(0.10) | $0.27 |
| Diluted | $(0.10) | $0.27 |
| Shares used to compute net income (loss) per share | ||
| Basic | 177,273,000 | 87,121,502 |
| Diluted | 177,273,000 | 87,150,666 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.